

Guidance for the surveillance of drug resistance in tuberculosis

Sixth edition



World Health
Organization



Guidance for the surveillance of drug resistance in tuberculosis

Sixth edition



**World Health
Organization**

Guidance for the surveillance of drug resistance in tuberculosis, sixth edition

ISBN 978-92-4-001802-0 (electronic version)

ISBN 978-92-4-001803-7 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO); <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>.

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Guidance for the surveillance of drug resistance in tuberculosis, sixth edition. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Designed by Fiona Byrne.

Contents

Acknowledgements	v
Abbreviations	vi
Introduction	1

Part I Principles of anti-TB drug resistance surveillance 5

1 Mechanisms of surveillance that produce data representative of a geographically-defined population	5
1.1 Continuous surveillance systems based on routine DST	6
1.2 Periodic surveys for estimating the burden of drug resistance	7
1.3 Sentinel surveillance systems for monitoring trends over time	8
2 Standardized stratification of results by patient characteristics	8
2.1 Patient treatment history classifications	8
2.2 Age groups, sex, HIV status and other patient sociodemographic and clinical factors	9
3 Quality-assured laboratory methods for determining resistance to anti-TB drugs	10
3.1 WHO-recommended methods for DST	10
3.2 Quality assurance of DST	15
4 Ethical considerations	18

Part II Planning and conducting a survey 21

5 Survey planning	21
5.1 Survey documents and other essential documents	21
5.2 Survey governance	23
5.3 Forming a national survey coordination team	24
5.4 Setting objectives	24
5.5 Defining the laboratory algorithm	25
5.6 Development of a protocol and time schedule	27
5.7 Minimum required facilities for a survey area	28
5.8 Sampling of cases	29
5.9 Budgeting	35
5.10 Training	35
5.11 Laboratory network preparedness	36
5.12 Pilot study	37

6	Survey implementation	38
6.1	Inclusion and exclusion criteria	38
6.2	Patient enrolment	38
6.3	Sample collection, storage and transport	41
6.4	Monitoring and evaluation	44
7	Data management, analysis and dissemination of survey results	45
7.1	Data management	45
7.2	Data analysis	47
7.3	Dissemination of survey findings, and policy and practice implications	49
	References	52
	Annexes	56
Annex 1	– Examples of survey algorithm designs	56
Annex 2	– Guide for developing a survey protocol	58
Annex 3	– Guide for survey participant information	63
Annex 4	– Example of a flowchart of enrolled patients	64
Annex 5	– Tables for summarizing main results	65
Annex 6	– Template for survey budget	67
Annex 7	– Template for a case report form	69
Annex 8	– Storage of sputum samples and culture isolates	71
Annex 9	– Safe shipment of specimens	74
Part I	– Shipping of culture isolates and sputum samples	74
Part II	– Inactivation and shipment of non-infectious specimens for molecular testing	76
Annex 10	– Template for assessment of survey preparedness and monitoring	80
Annex 11	– Template for assessment of the preparedness and monitoring of the central reference laboratory	83
Annex 12	– Template for on-site assessment of the preparedness and monitoring of health facilities	88
Annex 13	– Template for remote monitoring of health facilities	91
Annex 14	– Examples of quality and progress indicators	92

Acknowledgements

This sixth edition was written by Anna Dean and Olga Tosas Augustet.

Technical contributions and critical review were provided by the following staff from WHO Headquarters and Regional Offices: Vineet Bhatia, Philippe Glaziou, Nazir Ismail, Alexei Korobitsyn, Partha Pratim Mandal, Ernesto Montoro, Fukushi Morishita, Kyung Hyun Oh, Kalpeshsinh Rahevar and Hazim Timimi. Broad guidance was provided by Katherine Floyd and Tereza Kasaeva. Technical contributions and critical review were provided by the following consultants for WHO and TDR: Varalakshmi Elango, Eveline Klinkenberg and Jennifer Kealy.

The development of this document was guided by the following panel of external experts:

Andrea M. Cabibbe (San Raffaele Scientific Institute, Milan, Italy), Jacob Creswell (Stop TB Partnership, Geneva, Switzerland), Sophia Georghiou (Foundation for Innovative New Diagnostics, Geneva, Switzerland), Christopher Gilpin (International Organization for Migration, Geneva, Switzerland), Mourad Gumusboga (Institute of Tropical Medicine, Antwerp, Belgium), Jennifer Harris (Centers for Disease Prevention and Control, Atlanta, United States), Barry Kosloff (Zambart, Lusaka, Zambia), Ramya Kumar (Zambart, Lusaka, Zambia), Veriko Mirtskhulava (KNCV Tuberculosis Foundation, The Hague, The Netherlands), Christiaan Mulder (KNCV Tuberculosis Foundation, The Hague, The Netherlands), Sreenivas A. Nair (Stop TB Partnership, Geneva, Switzerland), Nnamdi Nwaneri (The Global Fund, Geneva, Switzerland), Anita Suresh (Foundation for Innovative New Diagnostics, Geneva, Switzerland), Elisa Tagliani (San Raffaele Scientific Institute, Milan, Italy), Sabira Tahseen (National TB Control Programme, Islamabad, Pakistan), Swapna Uplekar (Foundation for Innovative New Diagnostics, Geneva, Switzerland), Wayne van Gemert (Stop TB Partnership, Geneva, Switzerland) and Mohammed Yassin (The Global Fund, Geneva, Switzerland). Expert review was also provided by the Global Laboratory Initiative (GLI).

Portions of this updated edition are based on materials developed by Matteo Zignol.

Abbreviations

CPC	cetylpyridinium chloride
CTM	capture, tracking and management
DHIS2	District Health Information Software 2
DNA	deoxyribonucleic acid
DST	drug susceptibility testing
FIND	Foundation for Innovative New Diagnostics
GLI	Global Laboratory Initiative
Hr-TB	rifampicin-susceptible, isoniazid-resistant tuberculosis
IATA	International Air Transport Association
LPA	line probe assay
MAR	missing at random
RR-TB	rifampicin-resistant tuberculosis
MDR-TB	multidrug-resistant tuberculosis
MGIT	Mycobacteria Growth Indicator Tube
MTB	<i>Mycobacterium tuberculosis</i>
MoU	memorandum of understanding
MTA	material transfer agreement
NGS	next-generation sequencing
PPS	probability proportional to size
RR	rifampicin-resistant
RRDR	rifampicin resistance determining region
SOP	standard operating procedure
SRL	Supranational Reference Laboratory
TAT	turnaround time
TB	tuberculosis
WGS	whole genome sequencing
WHO	World Health Organization
XDR-TB	extensively drug-resistant tuberculosis

Introduction

This sixth edition of the *Guidance for the surveillance of drug resistance in tuberculosis* (TB) is an updated version of earlier editions published between 1994 and 2015 (1–5). Accurate diagnosis and treatment of TB should be available and accessible to all who need it, in line with the quest of the World Health Organization (WHO) to achieve universal health coverage, and to avert deaths from a preventable, treatable and curable disease. In 2014–2015, all WHO Member States committed to ending the TB epidemic by 2030 through the adoption of WHO's End TB Strategy and the United Nations Sustainable Development Goals (SDGs) (6,7). This guidance document supports their call for improved access to diagnostic testing for TB, including universal drug susceptibility testing (DST). Furthermore, it contributes to the 2019 World Health Assembly resolution (WHA72.5) for strengthened efforts to combat antimicrobial resistance (8), with an acknowledgement of its critical importance to TB.

This updated guidance incorporates experience gained from 25 years of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance (hereafter referred to as the Global Project), a project initiated by WHO and the International Union Against Tuberculosis and Lung Disease (The Union), supported by a global network of Supranational TB Reference Laboratories (SRLs) (9). This is the oldest and largest project for the surveillance of antimicrobial drug resistance in the world. The Global Project has served as a common platform for country, regional and global level evaluation of the magnitude and trends in anti-TB drug resistance. It has quantified the global burden of rifampicin-resistant (RR) TB, multidrug-resistant (MDR) TB¹ and of extensively drug-resistant (XDR) TB². More importantly, it has assisted countries in planning the scale-up of the management of drug-resistant TB by providing essential data on national burden and drug resistance patterns.

Since its launch in 1994, the Global Project has collected and analysed data on anti-TB drug resistance from national surveillance systems and periodic surveys from 169 countries, which together account for 99% of the world's estimated TB patients (10). Drug resistance surveillance data are published annually within the WHO Global Tuberculosis Report.

The aim of this document is to assist national TB programmes in developing the

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23961

